Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. From Wikipedia
Adaptimmune retains its two preclinical T cell therapies after selling Tecelra plus two clinical-stage programs in a $55 million deal that shifts commercialization staff to U.S. WorldMeds.
